Moloney Securities Asset Management LLC Sells 149 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Moloney Securities Asset Management LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,733 shares of the pharmaceutical company’s stock after selling 149 shares during the period. Moloney Securities Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $698,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of VRTX. Czech National Bank grew its position in shares of Vertex Pharmaceuticals by 6.2% in the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after purchasing an additional 3,260 shares in the last quarter. Whalen Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $662,000. Concord Wealth Partners grew its holdings in Vertex Pharmaceuticals by 32.6% during the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock valued at $1,413,000 after buying an additional 862 shares in the last quarter. Mizuho Securities USA LLC grew its holdings in Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after buying an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals by 19.4% during the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after buying an additional 55,739 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price objective for the company. Piper Sandler reduced their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Scotiabank raised their price target on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $502.58.

Vertex Pharmaceuticals Trading Down 2.5 %

VRTX opened at $469.32 on Monday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business has a 50 day simple moving average of $435.87 and a two-hundred day simple moving average of $462.49. The firm has a market capitalization of $120.86 billion, a price-to-earnings ratio of -235.84, a PEG ratio of 1.80 and a beta of 0.41.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.